Search results for "Replacement"

showing 10 items of 561 documents

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

2011

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particular GAG deposited and the specific enzyme mutation(s) present. Cardiac involvement has been reported in all MPS syndromes and is a common and early feature, particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more severe for left-sided than for right-sided valves), and hypertrophy are commonly present; conduction abnormalities, coronary artery and other vascular in…

AdultMalemedicine.medical_specialtyAdolescentMucopolysaccharidosisClinical SciencesHeart Valve DiseasesReviewComorbidityCoronary Artery DiseaseDiseaseMuscle hypertrophyCoronary artery diseaseElectrocardiographyVentricular hypertrophyTachycardiaInternal medicineGeneticsmedicineHumansGenetics(clinical)Age of OnsetSinusChildPreschoolGenetics (clinical)GlycosaminoglycansGenetics & Hereditymedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyHypertrophyAortic Valve StenosisEnzyme replacement therapyMucopolysaccharidosesMiddle Agedmedicine.diseaseLeft VentricularCausalityTachycardia SinusEchocardiographyChild PreschoolAortic valve stenosisCardiologyHypertrophy Left VentricularFemalebusinessElectrocardiographyJournal of Inherited Metabolic Disease
researchProduct

Use of topical tranexamic acid in primary total hip arthroplasty. Efficiency and safety. Our experience.

2019

Abstract Background and aim Intravenous tranexamic acid has been shown to reduce bleeding and the need for transfusions in total hip arthroplasty, although it has a theoretical risk of producing thromboembolic phenomena. Recently some papers have been published using the topical application of tranexamic acid, but the ideal administration protocol has not yet been clearly defined. The aim of this paper was to demonstrate that our protocol of topical tranexamic acid is effective and safe. Methods Prospective data collection from a case series of 80 primary hip arthroplasties, in which the following topical tranexamic acid protocol is used: 1.5 g diluted to a total volume of 60 ml were admini…

AdultMalemedicine.medical_specialtyBlood transfusionAdministration TopicalArthroplasty Replacement Hipmedicine.medical_treatmentBlood Loss SurgicalProspective data030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineClinical ProtocolsmedicineHumansBlood TransfusionOrthopedics and Sports MedicineProspective StudiesAged030222 orthopedicsAdministración tópica Artroplastia total cadera Topical administration Total hip arthroplasty Tranexamic acid Ácido tranexámicobusiness.industryFemoral canalMiddle AgedAntifibrinolytic AgentsSurgeryTreatment Outcomemedicine.anatomical_structureTranexamic AcidAcido tranexamicoFemaleSurgerybusinessTranexamic acidmedicine.drugTotal hip arthroplasty
researchProduct

Fabry disease: overall effects of agalsidase alfa treatment

2004

Background  Fabry disease is a rare X-linked disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A. Progressive accumulation of the substrate globotriaosylceramide in cells throughout the body leads to major organ failure and premature death. The Fabry Outcome Survey (FOS) is a European outcomes database which was established to collect data on the natural history of this little-known disease and to monitor the long-term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. This paper presents the first analysis of the FOS database on the effects of ERT on renal function, heart size, pain and quality of life. Design  The effects of 1 and 2 y…

AdultMalemedicine.medical_specialtyDatabases FactualClinical BiochemistryGlobotriaosylceramidePainRenal functionBiochemistrychemistry.chemical_compoundQuality of lifeInternal medicineHumansMedicineEnlarged heartBrief Pain Inventorybusiness.industryVascular diseaseMyocardiumGeneral MedicineEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryIsoenzymesTreatment Outcomechemistryalpha-GalactosidaseQuality of LifeFabry DiseaseFemaleHypertrophy Left VentricularbusinessFollow-Up StudiesGlomerular Filtration RateEuropean Journal of Clinical Investigation
researchProduct

Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

2003

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

AdultMalemedicine.medical_specialtyDiabetic neuropathyGabapentinAdolescentCyclohexanecarboxylic Acidsmedicine.medical_treatmentAcetatesGeneticsmedicineHumansBrief Pain InventoryAminesGenetics (clinical)gamma-Aminobutyric AcidPain Measurementbusiness.industryVascular diseaseEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryAnticonvulsantTreatment OutcomeAnesthesiaNeuropathic painFabry DiseaseNeuralgiaAnticonvulsantsGabapentinbusinessmedicine.drugJournal of inherited metabolic disease
researchProduct

Morbidity in 565 Type 2 Diabetic Patients According to Stage of Nephropathy

1998

Between 1988 and 1992, 565 type 2 diabetic patients were examined for nephropathy and diabetes-associated diseases during hospital treatment. Stages of nephropathy were defined as no clinical sign of nephropathy (N = 280), microalbuminuria (N = 38), overt proteinuria (N = 105), impaired renal function (N = 55), and chronic dialysis therapy (N = 87). In dialyzed patients, HbA1c averaged 6.8%, and, in the other groups, HbA1c was between 7.6% and 8.3% (normal range, 3.8%-6.1%). Cataract was not associated with the severity of nephropathy. Stroke was most common in the stage of renal insufficiency (34%). The following complications, as found in medical history or as current event, showed a sign…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMyocardial InfarctionBlood PressureGastroenterologyNephropathyCohort StudiesDiabetic nephropathyEndocrinologyRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineAlbuminuriaHumansCarotid StenosisDiabetic NephropathiesRenal replacement therapyAgedDiabetic RetinopathyProteinuriabusiness.industryMiddle Agedmedicine.diseaseSurgeryRenal Replacement TherapyCerebrovascular DisordersProteinuriaDiabetes Mellitus Type 2HypertensionAlbuminuriaFemaleHypertrophy Left VentricularMicroalbuminuriaMorbiditymedicine.symptombusinessKidney diseaseJournal of Diabetes and its Complications
researchProduct

Evaluation of total alloplastic temporo-mandibular joint replacement with two different types of prostheses : a three-year prospective study

2015

Background Temporo-Mandibular Joint (TMJ) replacement has been used clinically for years. The objective of this study was to evaluate outcomes achieved in patients with two different categories of TMJ prostheses. Material and Methods All patients who had a TMJ replacement (TMJR) implanted during the study period from 2006 through 2012 were included in this 3-year prospective study. All procedures were performed using the Biomet Microfixation TMJ Replacement System, and all involved replacing both the skull base component (glenoid fossa) and the mandibular condyle. Results Fifty-seven patients (38 females and 19 males), involving 75 TMJs with severe disease requiring reconstruction (39 unila…

AdultMalemedicine.medical_specialtyFossamedicine.medical_treatmentJoint ProsthesisDentistryTemporo mandibular jointCondyle03 medical and health sciences0302 clinical medicinestomatognathic systemMedicineHumansIn patientProspective StudiesArthroplasty ReplacementProspective cohort studyGeneral DentistryAgedbiologyTemporomandibular Jointbusiness.industryResearch030206 dentistryMiddle AgedTemporomandibular Joint Disordersbiology.organism_classification:CIENCIAS MÉDICAS [UNESCO]ArthroplastySurgeryTemporomandibular jointOrofacial Pain-TMJDSkullstomatognathic diseasesmedicine.anatomical_structureTreatment OutcomeOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryFemalebusinessFollow-Up Studies
researchProduct

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

2013

Globotriaosylceramide concentrations were assessed as potential predictors of change from baseline after 12 months by estimated glomerular filtration rate and left-ventricular mass index using pooled data from three randomized, placebo-controlled agalsidase alfa trials and open-label extensions of patients with Fabry disease.Males (aged 18 years or older) with Fabry disease received agalsidase alfa (0.2 mg/kg every other week for 12 months). A backward-elimination approach evaluated potential predictors (baseline estimated glomerular filtration rate and left-ventricular mass index; age at first dose; baseline and change from baseline at 12 months of globotriaosylceramide (urine, plasma); ur…

AdultMalemedicine.medical_specialtyHeart VentriclesUrologyGlobotriaosylceramideRenal functionUrinechemistry.chemical_compoundYoung Adultstomatognathic systemDouble-Blind MethodMedicineHumansRenal Insufficiency Chronicskin and connective tissue diseasesGenetics (clinical)Alpha-galactosidasebiologybusiness.industryTrihexosylceramidesvirus diseasesEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseasedigestive system diseasesRecombinant ProteinsIsoenzymesTreatment Outcomechemistryalpha-Galactosidasebiology.proteinDisease ProgressionBiomarker (medicine)Fabry Diseasesense organsbusinessBiomarkersKidney diseaseGlomerular Filtration RateGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

2007

Aims Anderson–Fabry disease (AFD) is an uncommon X-linked disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A. The Fabry Outcome Survey is a European database designed to monitor the long-term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. The aim of this study was to determine the prevalence and characteristics of cardiac disease in AFD patients. Methods and results Clinical and laboratory data were available in 714 patients from 11 countries (mean age 35 ± 17 years, 369 women, 336 treated). The prevalence of angina was 23 vs. 22%; palpitations and arrhythmias 27 vs. 26%; exertional dyspnoea 23 vs. 23%; and syncope 2 vs. 4%, in wom…

AdultMalemedicine.medical_specialtyHeart diseaseHeart DiseasesCardiomyopathyLeft ventricular hypertrophySyncopeAnginaRisk FactorsInternal medicinemedicinePalpitationsPrevalenceHumansVascular diseasebusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryEuropeIsoenzymesDyspneaTreatment OutcomeEchocardiographyalpha-GalactosidaseFabry DiseaseFemaleHypertrophy Left Ventricularmedicine.symptomCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateEuropean heart journal
researchProduct

Five times sit-to-stand test in subjects with total knee replacement: Reliability and relationship with functional mobility tests

2017

The objective was to determine the inter-observer and test/retest reliability of the "Five-repetition sit-to-stand" (5STS) test in patients with total knee replacement (TKR). To explore correlation between 5STS and two mobility tests. A reliability study was conducted among 24 (mean age 72.13, S.D. 10.67; 50% were women) outpatients with TKR. They were recruited from a traumatology unit of a public hospital via convenience sampling. A physiotherapist and trauma physician assessed each patient at the same time. The same physiotherapist realized a 5STS second measurement 45-60min after the first one. Reliability was assessed with intraclass correlation coefficients (ICCs) and Bland-Altman plo…

AdultMalemedicine.medical_specialtyHeteroscedasticityIntraclass correlationPosturePopulationBiophysicsTraumatologyCorrelation03 medical and health sciencessymbols.namesake0302 clinical medicineActivities of Daily LivingmedicineHumansOrthopedics and Sports MedicineArthroplasty Replacement KneeeducationGaitReliability (statistics)AgedAged 80 and overObserver Variationeducation.field_of_studybusiness.industryRehabilitationReproducibility of ResultsRecovery of Function030229 sport sciencesMiddle AgedConfidence intervalPearson product-moment correlation coefficientsymbolsPhysical therapyFemalebusiness030217 neurology & neurosurgeryGait & Posture
researchProduct

Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

AdultMalemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismGrowth hormoneGrowth hormone deficiency03 medical and health sciencesInsulin-like growth factor0302 clinical medicineEndocrinologySex FactorsInternal medicineGermanymedicineHumansDosingDwarfism PituitaryAgedDose-Response Relationship Drugbusiness.industryHuman Growth HormoneAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseClinical PracticeEndocrinologyTreatment OutcomeTransgender hormone therapy030220 oncology & carcinogenesisGh treatmentFemalebusinessReal world dataGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct